RU2300531C2 - Хинолиновые производные в качестве антагонистов нейропептида y - Google Patents

Хинолиновые производные в качестве антагонистов нейропептида y Download PDF

Info

Publication number
RU2300531C2
RU2300531C2 RU2004113207/04A RU2004113207A RU2300531C2 RU 2300531 C2 RU2300531 C2 RU 2300531C2 RU 2004113207/04 A RU2004113207/04 A RU 2004113207/04A RU 2004113207 A RU2004113207 A RU 2004113207A RU 2300531 C2 RU2300531 C2 RU 2300531C2
Authority
RU
Russia
Prior art keywords
pyrrolidin
methyl
alkyl
ylquinolin
ylmethoxy
Prior art date
Application number
RU2004113207/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2004113207A (ru
Inventor
Майкл Г. КЛУГ (US)
Майкл Г. КЛУГ
Патрицио МАТТЕИ (CH)
Патрицио МАТТЕИ
Вернер МЮЛЛЕР (CH)
Вернер Мюллер
Вернер НАЙДХАРТ (FR)
Вернер НАЙДХАРТ
Маттиас Генрих НЕТТЕКОФЕН (DE)
Маттиас Генрих НЕТТЕКОФЕН
Филипп ПФЛИЖЕ (FR)
Филипп Пфлиже
Жан-Марк ПЛАНШЕ (FR)
Жан-Марк ПЛАНШЕ
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2004113207A publication Critical patent/RU2004113207A/ru
Application granted granted Critical
Publication of RU2300531C2 publication Critical patent/RU2300531C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Structural Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2004113207/04A 2001-09-28 2002-09-20 Хинолиновые производные в качестве антагонистов нейропептида y RU2300531C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01123496.0 2001-09-28
EP01123496 2001-09-28

Publications (2)

Publication Number Publication Date
RU2004113207A RU2004113207A (ru) 2005-05-27
RU2300531C2 true RU2300531C2 (ru) 2007-06-10

Family

ID=8178804

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004113207/04A RU2300531C2 (ru) 2001-09-28 2002-09-20 Хинолиновые производные в качестве антагонистов нейропептида y

Country Status (23)

Country Link
US (4) US6787558B2 (enExample)
EP (1) EP1432421A1 (enExample)
JP (1) JP4187652B2 (enExample)
KR (1) KR100605765B1 (enExample)
CN (1) CN1289087C (enExample)
AR (1) AR040626A1 (enExample)
AU (1) AU2002342735B2 (enExample)
BR (1) BR0212929A (enExample)
CA (1) CA2460865C (enExample)
GT (1) GT200200197A (enExample)
HR (1) HRP20040272A2 (enExample)
HU (1) HUP0401481A2 (enExample)
IL (1) IL160750A0 (enExample)
MX (1) MXPA04002825A (enExample)
NO (1) NO20041235L (enExample)
NZ (1) NZ531517A (enExample)
PA (1) PA8555401A1 (enExample)
PE (1) PE20030603A1 (enExample)
PL (1) PL370414A1 (enExample)
RU (1) RU2300531C2 (enExample)
UY (1) UY27462A1 (enExample)
WO (1) WO2003028726A1 (enExample)
ZA (1) ZA200402359B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497821C2 (ru) * 2008-01-28 2013-11-10 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННОГО-ТИО (ИЛИ -ОКСО-)-2-АМИНО-ХИНОЛИНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ (BACE)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
PT2182950T (pt) * 2007-05-17 2017-09-11 Helperby Therapeutics Ltd Uso de compostos 4-(pirrolidin-1-il)quinolina para eliminação de microrganismos clinicamente latentes
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2362731B1 (en) 2008-10-31 2016-04-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
HRP20240805T1 (hr) 2013-06-05 2024-09-27 Bausch Health Ireland Limited Ultra-pročišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i uporabe
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9663468B2 (en) 2014-01-10 2017-05-30 Northwestern University 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
US9212144B2 (en) * 2014-01-10 2015-12-15 Northwestern University 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
JP6969800B2 (ja) * 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換2,4−ジアミノ−キノリン誘導体
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
WO2020160151A1 (en) * 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
WO2020231739A2 (en) * 2019-05-10 2020-11-19 Antidote Ip Holdings, Llc Compounds and methods for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1477247A3 (ru) * 1985-05-07 1989-04-30 Алкалоида Ведьесети Дьяр (Инопредприятие) Способ получени триазолилхинолиновых производных или их солей присоединени кислот
WO2001002385A1 (fr) * 1999-06-30 2001-01-11 Aventis Cropscience S.A. Derives de 1-(quinolin-4-yl)-1h-pyrazole et leur utilisation comme fongicides
WO2001023389A2 (en) * 1999-09-30 2001-04-05 Neurogen Corporation Certain alkylene diamine-substituted heterocycles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272824A (en) 1962-12-06 1966-09-13 Norwich Pharma Co 4-amino-6, 7-di(lower) alkoxyquinolines
US4035367A (en) 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
AU719392B2 (en) 1996-10-01 2000-05-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
US6199042B1 (en) * 1998-06-19 2001-03-06 L&H Applications Usa, Inc. Reading system
ATE293970T1 (de) 1998-08-14 2005-05-15 Hoffmann La Roche Lipasehemmer enthaltende pharmazeutische zusammensetzungen
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1477247A3 (ru) * 1985-05-07 1989-04-30 Алкалоида Ведьесети Дьяр (Инопредприятие) Способ получени триазолилхинолиновых производных или их солей присоединени кислот
WO2001002385A1 (fr) * 1999-06-30 2001-01-11 Aventis Cropscience S.A. Derives de 1-(quinolin-4-yl)-1h-pyrazole et leur utilisation comme fongicides
WO2001023389A2 (en) * 1999-09-30 2001-04-05 Neurogen Corporation Certain alkylene diamine-substituted heterocycles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497821C2 (ru) * 2008-01-28 2013-11-10 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННОГО-ТИО (ИЛИ -ОКСО-)-2-АМИНО-ХИНОЛИНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ (BACE)

Also Published As

Publication number Publication date
ZA200402359B (en) 2005-05-03
AU2002342735B2 (en) 2005-09-22
CN1289087C (zh) 2006-12-13
RU2004113207A (ru) 2005-05-27
NO20041235L (no) 2004-03-24
PL370414A1 (en) 2005-05-30
KR100605765B1 (ko) 2006-07-31
CN1607951A (zh) 2005-04-20
US20060148794A1 (en) 2006-07-06
US20040259858A1 (en) 2004-12-23
JP2005508923A (ja) 2005-04-07
IL160750A0 (en) 2004-08-31
US7064134B2 (en) 2006-06-20
US7166589B2 (en) 2007-01-23
KR20040039442A (ko) 2004-05-10
PA8555401A1 (es) 2003-07-28
UY27462A1 (es) 2003-04-30
JP4187652B2 (ja) 2008-11-26
CA2460865C (en) 2008-09-09
HUP0401481A2 (hu) 2004-12-28
US20060063758A1 (en) 2006-03-23
WO2003028726A1 (en) 2003-04-10
CA2460865A1 (en) 2003-04-10
HK1074176A1 (en) 2005-11-04
AR040626A1 (es) 2005-04-13
EP1432421A1 (en) 2004-06-30
PE20030603A1 (es) 2003-07-12
US6787558B2 (en) 2004-09-07
US7012073B2 (en) 2006-03-14
US20030158179A1 (en) 2003-08-21
NZ531517A (en) 2005-11-25
BR0212929A (pt) 2004-10-13
HRP20040272A2 (en) 2004-08-31
MXPA04002825A (es) 2004-07-02
GT200200197A (es) 2003-06-19

Similar Documents

Publication Publication Date Title
RU2300531C2 (ru) Хинолиновые производные в качестве антагонистов нейропептида y
KR100621287B1 (ko) 신경 펩타이드 y 수용체에 대한 리간드로서의 퀴놀린유도체
US7265125B2 (en) Neuropeptide Y antagonists
AU2002342735A1 (en) Quinoline derivatives as neuropeptide Y antagonists
RU2298002C2 (ru) Производные хинолина в качестве антагонистов npy
RU2296757C2 (ru) Производные хиназолина
JP2003502317A (ja) 新規化合物、その使用および製造

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080921